SOFOSBUVIR in Croatian translation

• sofosbuvir
• sofosbuvirom
• sofosbuvira
• sofosbuviru

Examples of using Sofosbuvir in English and their translations into Croatian

The parent sofosbuvir accounts for approximately 4% of drug-related material systemic exposure see section 5.2.
Na prekursor sofosbuvira otpada približno 4% sistemske izloženosti tvarima povezanima s lijekom vidjeti dio 5.2.

Table 14: Treatment outcome in HCV genotype 1 infected patients without cirrhosis receiving 12 weeks simeprevir+ sofosbuvir, with or without ribavirin study HPC2002.
Tablica 14: Ishod liječenja u bolesnika inficiranih HCV genotipom 1 bez ciroze koji su primali 12 tjedana simeprevir+ sofosbuvir, s ili bez ribavirina ispitivanje HPC2002.

The pharmacokinetics of ledipasvir, sofosbuvir and GS-331007 in paediatric patients have not been established see section 4.2.
Farmakokinetika ledipasvira, sofosbuvira i GS-331007 u pedijatrijskih pacijenata nije ustanovljena vidjeti dio 4.2.

The most common adverse drug reactions occurring in subjects receiving sofosbuvir and ribavirin or sofosbuvir, ribavirin and peginterferon alfa were fatigue,
Najčešće nuspojave na lijek koje su nastajale u ispitanika koji su primali sofosbuvir i ribavirin ili sofosbuvir, ribavirin i peginterferon alfa bile su umor,

limited amount of data(less than 300 pregnancy outcomes) from the use of ledipasvir, sofosbuvir or Harvoni in pregnant women.
su podaci o primjeni ledipasvira, sofosbuvira ili lijeka Harvoni u trudnica ograničeni manje od 300 trudnoća.

Co-administration of Harvoni with oxcarbazepine is expected to decrease the concentration of ledipasvir and sofosbuvir leading to reduced therapeutic effect of Harvoni.
Očekuje se da će istovremena primjena lijeka Harvoni s okskarbazepinom smanjiti koncentraciju ledipasvira i sofosbuvira i tako dovestido smanjenog terapijskog učinka lijeka Harvoni.

Epclusa is available as tablets which contain 400 mg sofosbuvir and 100 mg velpatasvir.
Lijek Epclusa dostupan je u obliku tableta koje sadrže 400 mg sofosbuvira i 100 mg velpatasvira.

For previously treated patients with genotype 1 HCV infection, no data exists with the combination of sofosbuvir, peginterferon alfa and ribavirin.
Za prethodno liječene bolesnike s infekcijom genotipom 1 HCV-a ne postoje podaci za kombinaciju sofosbuvira, peginterferona i ribavirina.

of co-administered drug pharmacokinetics with/without sofosbuvir and mean ratio of sofosbuvir and GS-331007 with/without co-administered drug.
farmakokinetike istodobno primijenjenog lijeka sa/bez sofosbuvira i srednja vrijednost omjera sofosbuvira i GS-331007 sa/bez istodobno primijenjenog lijeka.

daclatasvir in combination with sofosbuvir for 12 weeks, patients with HCV genotype 3 in Study ALLY-3.
daklatazvir u kombinaciji sa sofosbuvirom tijekom 12 tjedana, bolesnici s HCV-om genotipa 3 u ispitivanju ALLY-3.

Among patients who achieved SVR12 with daclatasvir and sofosbuvir(± ribavirin) with a median duration of post-SVR12 follow-up of 15 months,
Među bolesnicima koji su postigli SVR12 uz primjenu daklatazvira i sofosbuvira(± ribavirin),

Co-administration will significantly decrease ledipasvir and sofosbuvir plasma concentrations and could result in loss of efficacy of Harvoni see section 4.5.
Istodobna primjena značajno će smanjiti koncentracije ledipasvira i sofosbuvira u plazmi i tako može dovesti do gubitka djelotvornosti lijeka Harvoni vidjeti dio 4.5.

The sofosbuvir resistance-associated substitution S282T emerged in only 1 non-SVR12 patient infected with genotype 3.
Supstitucija S282T, koja je povezana s rezistencijom na sofosbuvir, pojavila se u samo 1 bolesnika s infekcijom genotipom 3 koji nije postigao SVR12.

Co-administration will significantly decrease sofosbuvir or velpatasvir plasma concentrations
Istodobna primjena značajno će smanjiti koncentraciju sofosbuvira ili velpatasvira u plazmi

The sofosbuvir resistance-associated substitution S282T in NS5B was not detected in any virologic failure isolate from the Phase 3 studies.
Supstitucija S282T povezana s rezistencijom na sofosbuvir u NS5B nije bila otkrivena ni u jednom izolatu kod virološkog neuspjeha u ispitivanjima faze 3.

Following a single 400 mg dose of sofosbuvir, a 4 hour haemodialysis removed 18% of administered dose see section 4.2.
Nakon jedne doze od 400 mg sofosbuvira, tijekom 4 sata hemodijalize uklonilo se 18% primijenjene doze vidjeti dio 4.2.

The clinical data to support the use of Daklinza and sofosbuvir in patients infected with HCV genotypes 4
Klinički podaci koji podupiru primjenu lijeka Daklinza i sofosbuvira u bolesnika s infekcijom HCV-om genotipa 4

Safety and efficacy of ledipasvir/sofosbuvir have been established in patients with decompensated cirrhosis see section 5.1.
Sigurnost i djelotvornost ledipasvira/sofosbuvira ustanovljene su u pacijenata s dekompenziranom cirozom vidjeti dio 5.1.

Sofosbuvir and GS-331007 AUC0-24 and Cmax were similar in healthy adult subjects
AUC0-24 i Cmax sofosbuvira i GS-331007 bile su slične u zdravih odraslih ispitanika

Sofosbuvir and GS-331007 AUCs are near dose proportional over the dose range of 200 mg to 400 mg.
AUC sofosbuvira i GS-331007 bili su gotovo proporcionalni dozi u rasponu doza od 200 mg do 400 mg.